Bridgebio Pharma (BBIO)
NASDAQ:BBIO
Want to see BBIO full AI Analyst Report?
BBIO Stock Chart & Stats
$76.75
-$0.10(-0.35%)
At close: 4:00 PM EST
$76.75
-$0.10(-0.35%)
Day’s Range― - ―
52-Week Range$31.77 - $84.94
Previous CloseN/A
Volume379.31K
Average Volume (3M)2.82M
Market Cap
$13.54B
Enterprise Value$16.04B
Total Cash (Recent Filing)$940.19M
Total Debt (Recent Filing)$3.38B
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Jul 30, 2026EPS Estimate
-0.59Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.75
Shares Outstanding195,861,240
10 Day Avg. Volume3,026,240
30 Day Avg. Volume2,824,691
Financial Highlights & Ratios
PEG Ratio-0.65
Price to Book (P/B)-7.27
Price to Sales (P/S)30.05
P/FCF Ratio-33.75
Enterprise Value/Market Cap1.19
Enterprise Value/Revenue27.66
Enterprise Value/Gross Profit29.50
Enterprise Value/Ebitda-26.69
Forecast
1Y Price Target
$107.41Price Target Upside39.95% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering18
EPS Forecast (FY)-2.17
Revenue Forecast (FY)$955.51M
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsThe FORTIFY pivotal study met its pre-specified primary and secondary endpoints with a favorable safety profile, supporting BBP-418's potential as a disease-modifying treatment for limb-girdle muscular dystrophy.
Commercial AdoptionSustained prescription growth for Attruby and physician preference versus existing therapy indicate meaningful uptake in transthyretin cardiomyopathy and support the franchise's revenue potential.
Pipeline Value And FinancingMultiple late-stage programs and the potential to secure a Priority Review Voucher could provide non-dilutive capital and broaden the company's commercial portfolio beyond a single launch.
Bears Say
Generic Competition RiskInvestor concern about potential generic tafamidis competition could create a market overhang and weigh on the stock through uncertainty about future market share.
Pricing PressurePossible generic entry may reduce pricing power in the disease area, which could lower revenue per patient and compress profit margins for marketed therapies.
Regulatory Execution RiskRegulatory approvals depend on the timing and outcome of agency interactions, introducing execution risk that could delay product launches and expected cash flow improvements.
BridgeBio Pharma News
BBIO FAQ
What was Bridgebio Pharma’s price range in the past 12 months?
Bridgebio Pharma lowest stock price was $31.77 and its highest was $84.94 in the past 12 months.
What is Bridgebio Pharma’s market cap?
Bridgebio Pharma’s market cap is $13.54B.
When is Bridgebio Pharma’s upcoming earnings report date?
Bridgebio Pharma’s upcoming earnings report date is Jul 30, 2026 which is in 67 days.
How were Bridgebio Pharma’s earnings last quarter?
Bridgebio Pharma released its earnings results on May 07, 2026. The company reported -$0.84 earnings per share for the quarter, missing the consensus estimate of -$0.679 by -$0.161.
Is Bridgebio Pharma overvalued?
According to Wall Street analysts Bridgebio Pharma’s price is currently Undervalued.
Does Bridgebio Pharma pay dividends?
Bridgebio Pharma does not currently pay dividends.
What is Bridgebio Pharma’s EPS estimate?
Bridgebio Pharma’s EPS estimate is -0.59.
How many shares outstanding does Bridgebio Pharma have?
Bridgebio Pharma has 195,861,240 shares outstanding.
What happened to Bridgebio Pharma’s price movement after its last earnings report?
Bridgebio Pharma reported an EPS of -$0.84 in its last earnings report, missing expectations of -$0.679. Following the earnings report the stock price went down -0.089%.
Which hedge fund is a major shareholder of Bridgebio Pharma?
Currently, no hedge funds are holding shares in BBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BridgeBio Pharma Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$107.41 (39.95% Upside)
$107.41 (39.95% Upside)
Blogger Sentiment
Bullish
BBIO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 2.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Neutral
Last 7 Days ▼ 0.7%
Last 30 Days ▲ 1.3%
Last 30 Days ▲ 1.3%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
109.64%
12-Months-Change
Fundamentals
Return on Equity
36.00%
Trailing 12-Months
Asset Growth
55.50%
Trailing 12-Months
Company Description
Bridgebio Pharma
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1; and BBP-711 for the treatment of hyperoxaluria, as well as patients suffering from recurrent kidney stones. In addition, it engages in developing products for Mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and The Regents of the University of California; Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.
BBIO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong commercial momentum (notably Atruvio revenue growth: $180.6M, +24% QoQ, +392% YoY), robust cash runway ($940.2M) and clear pipeline progress with active launch preparations (LGMD2I NDA, ADH1 patient ID, positive PROPEL‑3 for achondroplasia). Management emphasized clinical differentiation backed by real‑world evidence and favorable long‑term economics, while acknowledging short‑term expense pressures (operating expenses +$72.1M) and an operating loss of $106M that should narrow later in the year. Competitive risks, diagnostic supply issues, and the prior‑year milestone timing created some near‑term revenue volatility, but overall the company presented multiple tangible positives that outweigh the listed challenges.View all BBIO earnings summariesBBIO Stock 12 Month Forecast
Average Price Target
$107.41
▲(39.95% Upside)
Technical Analysis
BioMarin Pharmaceutical
―
Exelixis
―
Ionis Pharmaceuticals
―
Madrigal Pharmaceuticals
―
Moderna
―
Ownership Overview
13.46% Insiders
24.48% Mutual Funds
38.63% Other Institutional Investors
8.91% Public Companies and Individual Investors